Insilico Medicine launched what it describes as the first Drug Discovery and Development Benchmark-as-a-Service targeting frontier AI and foundation models. The framework is built as a “blind test” and a public leaderboard to evaluate whether AI systems can make meaningful scientific decisions rather than recall training data patterns. The company says it draws on validated programs and long experience to stress-test real-world drug discovery workflows.